Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols Sells 3,334 Shares of Stock

Alkermes plc (NASDAQ:ALKS) SVP Christian Todd Nichols sold 3,334 shares of the company’s stock in a transaction that occurred on Tuesday, June 10th. The stock was sold at an average price of $31.09, for a total transaction of $103,654.06. Following the completion of the sale, the senior vice president now directly owns 86,208 shares of the company’s stock, valued at approximately $2,680,206.72. This represents a 3.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Christian Todd Nichols also recently made the following trade(s):

• On Monday, June 9th, Christian Todd Nichols sold 3,333 shares of Alkermes stock. The stock was sold at an average price of $31.95, for a total transaction of $106,489.35.

Alkermes Price Performance

ALKS stock opened at $31.06 on Wednesday. Alkermes plc has a 52-week low of $22.90 and a 52-week high of $36.45. The company’s 50 day simple moving average is $29.58 and its 200-day simple moving average is $31.00. The firm has a market capitalization of $5.12 billion, a P/E ratio of 14.31, a P/E/G ratio of 2.20 and a beta of 0.47.

Alkermes (NASDAQ:ALKS) last released its quarterly earnings data on Thursday, May 1st. The company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.32 by ($0.19). The company had revenue of $306.51 million during the quarter, compared to analyst estimates of $307.53 million. Alkermes had a net margin of 23.57% and a return on equity of 30.80%. The firm’s quarterly revenue was down 12.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.43 EPS. Sell-side analysts predict that Alkermes plc will post 1.31 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on ALKS. HC Wainwright reiterated a “neutral” rating on shares of Alkermes in a report on Friday, May 2nd. Royal Bank of Canada boosted their target price on shares of Alkermes from $39.00 to $40.00 and gave the stock a “sector perform” rating in a report on Friday, May 2nd. UBS Group reiterated a “sector perform” rating on shares of Alkermes in a report on Monday, April 28th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Alkermes from $40.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, March 27th. Finally, Robert W. Baird boosted their target price on shares of Alkermes from $38.00 to $41.00 and gave the stock an “outperform” rating in a report on Friday, May 2nd. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Alkermes has a consensus rating of “Moderate Buy” and a consensus target price of $38.85.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. Venturi Wealth Management LLC acquired a new position in Alkermes in the 4th quarter valued at approximately $25,000. Twin Tree Management LP acquired a new position in Alkermes in the 1st quarter valued at approximately $29,000. Brooklyn Investment Group increased its stake in Alkermes by 1,071.1% in the 1st quarter. Brooklyn Investment Group now owns 1,054 shares of the company’s stock valued at $35,000 after buying an additional 964 shares during the period. Quantbot Technologies LP increased its stake in Alkermes by 54.5% in the 1st quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after buying an additional 385 shares during the period. Finally, EverSource Wealth Advisors LLC increased its stake in Alkermes by 106.2% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,635 shares of the company’s stock valued at $47,000 after buying an additional 842 shares during the period. Institutional investors and hedge funds own 95.21% of the company’s stock.

About Alkermes

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.